The synthesis of CDMO from LiOH and EMD has been investigated by thermogravimetry and pow- der X-ray diffraction analysis.The results showed that it took place from below 100 to 400℃.When the proportion of Li:Mn in t...The synthesis of CDMO from LiOH and EMD has been investigated by thermogravimetry and pow- der X-ray diffraction analysis.The results showed that it took place from below 100 to 400℃.When the proportion of Li:Mn in the starting mixture was 3:7,the measured weight loss during this process was 7.40% for heat-treated EMD and 8.33% for non-heat-treated EMD.Based on these data and X-ray diffraction results the obtained product would be 3LiMn204 - MnO2.This material was es- sentially amorphous.It can insert 4.7 Li per 3LiMn_2O_4·MnO_2,leading to a capacity of 170- 200 mAh/g and demonstrated reasonable discharge and recharge cycle performance for both test cells and practical batteries.展开更多
CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role...CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within these sectors are now leveraging the expertise of CDMOs through technology transfers to foster innovation and enhance the development of new drug products. In the extensive field of drug development, technology transfer plays a crucial role at multiple stages, ranging from preclinical phases to commercialization. By working closely with drug developers, CDMOs can ensure that technologies are transferred seamlessly between phases of drug development, allowing for a more efficient and cost-effective development process. CDMOs also bring a wealth of experience in various areas of drug development, including process development, analytical testing, quality control, and manufacturing. This expertise, combined with a focus on innovation, can help drug developers to overcome technical challenges and optimize their drug development programs. CDMOs can provide drug developers with various manufacturing capabilities, from small-scale clinical trials to large-scale commercial production. This flexibility allows drug developers to focus on their core competencies while relying on CDMOs to provide the necessary infrastructure and support for drug manufacturing. The critical role of CDMOs in advancing pharmaceutical innovation in phase-appropriate technology transfer where there will be a lot of effort and patience with strong technical expertise is required. This article explores the various types of Technology transfer from preclinical to commercial stages and successful strategies to foster innovation.展开更多
Objective To analyze the development status of contract development manufacturing organization(CDMO)at home and abroad,and to make some suggestions for the development of CDMO in China.Methods The relevant literature ...Objective To analyze the development status of contract development manufacturing organization(CDMO)at home and abroad,and to make some suggestions for the development of CDMO in China.Methods The relevant literature was searched and reviewed,and the development status of CDMOs in the United States,France,Japan and China was compared from the aspects of market scale,development process,development focus,advantages and disadvantages,and policy support.Then,some suggestions for the development of CDMO enterprises in China were summarized.Results and Conclusion Through the comparison of CDMO development at home and abroad,it can be seen that China started CDMO late,there were many technical barriers and its globalization layout were not sufficient.However,the development trend was good and it focused on the field of chemical drugs and biological drugs to constantly develop innovative drugs.China needs to continuously improve its own technical capabilities to carry out innovative research.Therefore,cost reduction and efficiency increase will be the key elements for the development of CDMOs,and they are expected to have a rapid and comprehensive development in the future.展开更多
近年来,随着《“十四五”生物经济发展规划》《“十四五”医药工业发展规划》等一系列国家政策的深入实施,我国医药产业正迎来新一轮结构化升级。政策导向明确鼓励新药研发能力提升,推动医药产业链协同与专业化分工。在此背景下,合同定...近年来,随着《“十四五”生物经济发展规划》《“十四五”医药工业发展规划》等一系列国家政策的深入实施,我国医药产业正迎来新一轮结构化升级。政策导向明确鼓励新药研发能力提升,推动医药产业链协同与专业化分工。在此背景下,合同定制生产组织(Contract Development and Manufacturing Organization,以下简称CDMO企业)作为医药创新体系的关键环节,正逐步从传统原料药、制剂生产向高附加值的创新药、生物药及复杂制剂领域延伸。这一趋势不仅带动了研发与生产外包市场的扩容,也对药品包装服务,尤其是二次包装环节,提出了更高要求。展开更多
The scintillation properties of a CdMoO4 crystal have been investigated experimentally.The fluorescence yields and decay times measured from 22 K to 300 K demonstrate that CdMoO4 crystal is a good candidate for an abs...The scintillation properties of a CdMoO4 crystal have been investigated experimentally.The fluorescence yields and decay times measured from 22 K to 300 K demonstrate that CdMoO4 crystal is a good candidate for an absorber for a bolometer readout,for both heat and scintillation signals.The results from Monte Carlo studies,taking the backgrounds from 2ν2β of^100 42Mo ^116 48Cd） and internal trace nuclides ^214Bi and ^208Tl into account,show that the expected sensitivity of a CdMoO4 bolometer for neutrinoless double beta decay experiments with an exposure of 100kg·years is one order of magnitude higher than those of the current sets of the limT1/2^0νββ of ^100 42Mo and ^116 48Cd.展开更多
文摘The synthesis of CDMO from LiOH and EMD has been investigated by thermogravimetry and pow- der X-ray diffraction analysis.The results showed that it took place from below 100 to 400℃.When the proportion of Li:Mn in the starting mixture was 3:7,the measured weight loss during this process was 7.40% for heat-treated EMD and 8.33% for non-heat-treated EMD.Based on these data and X-ray diffraction results the obtained product would be 3LiMn204 - MnO2.This material was es- sentially amorphous.It can insert 4.7 Li per 3LiMn_2O_4·MnO_2,leading to a capacity of 170- 200 mAh/g and demonstrated reasonable discharge and recharge cycle performance for both test cells and practical batteries.
文摘CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within these sectors are now leveraging the expertise of CDMOs through technology transfers to foster innovation and enhance the development of new drug products. In the extensive field of drug development, technology transfer plays a crucial role at multiple stages, ranging from preclinical phases to commercialization. By working closely with drug developers, CDMOs can ensure that technologies are transferred seamlessly between phases of drug development, allowing for a more efficient and cost-effective development process. CDMOs also bring a wealth of experience in various areas of drug development, including process development, analytical testing, quality control, and manufacturing. This expertise, combined with a focus on innovation, can help drug developers to overcome technical challenges and optimize their drug development programs. CDMOs can provide drug developers with various manufacturing capabilities, from small-scale clinical trials to large-scale commercial production. This flexibility allows drug developers to focus on their core competencies while relying on CDMOs to provide the necessary infrastructure and support for drug manufacturing. The critical role of CDMOs in advancing pharmaceutical innovation in phase-appropriate technology transfer where there will be a lot of effort and patience with strong technical expertise is required. This article explores the various types of Technology transfer from preclinical to commercial stages and successful strategies to foster innovation.
文摘Objective To analyze the development status of contract development manufacturing organization(CDMO)at home and abroad,and to make some suggestions for the development of CDMO in China.Methods The relevant literature was searched and reviewed,and the development status of CDMOs in the United States,France,Japan and China was compared from the aspects of market scale,development process,development focus,advantages and disadvantages,and policy support.Then,some suggestions for the development of CDMO enterprises in China were summarized.Results and Conclusion Through the comparison of CDMO development at home and abroad,it can be seen that China started CDMO late,there were many technical barriers and its globalization layout were not sufficient.However,the development trend was good and it focused on the field of chemical drugs and biological drugs to constantly develop innovative drugs.China needs to continuously improve its own technical capabilities to carry out innovative research.Therefore,cost reduction and efficiency increase will be the key elements for the development of CDMOs,and they are expected to have a rapid and comprehensive development in the future.
文摘近年来,随着《“十四五”生物经济发展规划》《“十四五”医药工业发展规划》等一系列国家政策的深入实施,我国医药产业正迎来新一轮结构化升级。政策导向明确鼓励新药研发能力提升,推动医药产业链协同与专业化分工。在此背景下,合同定制生产组织(Contract Development and Manufacturing Organization,以下简称CDMO企业)作为医药创新体系的关键环节,正逐步从传统原料药、制剂生产向高附加值的创新药、生物药及复杂制剂领域延伸。这一趋势不仅带动了研发与生产外包市场的扩容,也对药品包装服务,尤其是二次包装环节,提出了更高要求。
基金Supported by National Natural Science Foundation of China(11275199)
文摘The scintillation properties of a CdMoO4 crystal have been investigated experimentally.The fluorescence yields and decay times measured from 22 K to 300 K demonstrate that CdMoO4 crystal is a good candidate for an absorber for a bolometer readout,for both heat and scintillation signals.The results from Monte Carlo studies,taking the backgrounds from 2ν2β of^100 42Mo ^116 48Cd） and internal trace nuclides ^214Bi and ^208Tl into account,show that the expected sensitivity of a CdMoO4 bolometer for neutrinoless double beta decay experiments with an exposure of 100kg·years is one order of magnitude higher than those of the current sets of the limT1/2^0νββ of ^100 42Mo and ^116 48Cd.
